Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of LRRK2 Inhibitors through Computational Drug Repurposing.

ACS chemical neuroscience - 1 Feb 2023

Tan Shuoyan, Lu Ruiqiang, Yao Dahong, Wang Jun, Gao Peng, Xie Guotong, Liu Huanxiang, Yao Xiaojun

Abstract excerpt

Parkinson's disease (PD) is the second most common neurodegenerative disorder that affects more than ten million people worldwide. However, the current PD treatments are still limited and alternative treatment strategies are urgently required. Leucine-rich repeat kinase 2 (LRRK2) has been recognized as a promising target for PD treatment. However, there are no approved LRRK2 inhibitors on the market. To rapidly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Repositioning
Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Docking Simulation

Share to Mutation

Share to Parkinson Disease

Source

Identifiers

PMID: 36649061
DOI: 10.1021/acschemneuro.2c00672

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of LRRK2 Inhibitors through Computational Drug Repurposing.PMID 36649061Read ↗

Decoding Inhibitor Egression from Wild-Type and G2019S Mutant LRRK2 Kinase: Insights into Unbinding Mechanisms for Precision Drug Design in Parkinson's Disease.Semantic proximity Read ↗

Discovery of potent and selective LRRK2 inhibitors with preserved activity against the G2019S mutant via multi-stage virtual screening.Semantic proximity Read ↗

Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain.Semantic proximity Read ↗

Drug repurposing for SARS-CoV-2: a high-throughput molecular docking, molecular dynamics, machine learning, and DFT studySemantic proximity Read ↗

In-silico Drug Repurposing Pipeline for Epilepsy: Integrating Deep Learning and Structure-based ApproachesSemantic proximity Read ↗

Integrated Docking and Enhanced Sampling Based Selection of Repurposing Drugs for SARS-CoV-2 by Targeting Host Dependent FactorsSemantic proximity Read ↗

<i>In-silico</i> Drug Repurposing Pipeline for Epilepsy: Integrating Deep Learning and Structure-based ApproachesSemantic proximity Read ↗

A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19Semantic proximity Read ↗

Multi-method computational evaluation of the inhibitors against leucine-rich repeat kinase 2 G2019S mutant for Parkinson's diseaseSemantic proximity Read ↗

Multi-method computational evaluation of the inhibitors against leucine-rich repeat kinase 2 G2019S mutant for Parkinson's disease.Semantic proximity Read ↗

Structure-Based Virtual Screening and De Novo Design to Identify Submicromolar Inhibitors of G2019S Mutant of Leucine-Rich Repeat Kinase 2.Semantic proximity Read ↗

Molecular Modeling Study on the Interaction Mechanism between the LRRK2 G2019S Mutant and Type I Inhibitors by Integrating Molecular Dynamics Simulation, Binding Free Energy Calculations, and Pharmacophore Modeling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.